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Abstract: Almost every boy that has Duchenne Muscular Dystrophy (DMD) will develop cardiac problems. Whereas, it 
used to be respiratory problems that was the main cause of death in these DMD boys; with the advent of better respiratory 
care it is now the cardiac involvement that is becoming the most common cause of their death. Once the heart is affected, 
there is progressive deterioration in the function of the heart over time. The main problem is the death of the cardiomyo-
cytes. The cause of the cardiomyocyte death is due to the loss of dystrophin, this makes the sarcolemma more susceptible 
to damage, and leads to a cascade of calcium influx, calcium activated proteases and ultimately the death of the cardio-
myocyte. The dead cardiomyocytes are replaced by fibrotic tissue, which results in a dilated cardiomyopathy (DCM)  
developing, which begins in the base of the left ventricle and progresses to involve the entire left ventricle. The treatments 
used for the DMD cardiomyopathy are based on ones designed for other forms of cardiac weakness and include ACE-
inhibitors and -blockers. New therapies based around the pathophysiology in DMD are now being introduced. This  
review will look at the pathophysiology of the cardiac problems in DMD and how the various animal models that are 
available can be used to design new treatment options for DMD boys. 
Keywords: Cardiomyopathy, muscular dystrophy.  
INTRODUCTION 
  Duchenne muscular dystrophy (DMD) is a lethal X-
linked recessive disorder that affects 1 in 3,500 live newborn 
males [1, 2]. The disorder is caused by mutations in the dys-
trophin gene, usually deletions or point mutations that lead to 
a shift in the reading frame and produce a stop codon, thus 
causing the complete loss or very reduced and deficient syn-
thesis of dystrophin protein, which forms an integral part of 
the dystrophin-glycoprotein complex (DGC) [3]. A major 
function of the DGC is to connect the subsarcolemmal cy-
toskeleton to the extracellular matrix, with dystrophin form-
ing the intracellular link acting like a shock absorber as the 
cell contracts and moves (Fig. 1). Dystrophin is one of the 
largest proteins in the body at 427kDa and it is not just ex-
pressed in skeletal muscle but also in cardiac muscle as well 
as in the brain. So although DMD is described as a primary 
degenerative condition of the skeletal muscle there are addi-
tional detrimental effects on the function of the heart and 
around 90% of DMD boys will develop severe cardiac prob-
lems [4]. The female carriers of DMD are usually free of 
skeletal muscle symptoms, but around 30% will develop 
some skeletal muscle problems and about 10% of these 
women will also develop some signs of heart weakness. 
These manifesting carriers are due to a non-random inactiva-
tion of the X chromosomes, leading to a predominant ex-
pression of the X chromosome that carries the mutation in  
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the dystrophin gene. Becker muscular dystrophy (BMD) is a 
milder variant of DMD, also caused by mutations in the dys-
trophin gene. In BMD the deletions usually do not cause a 
shift in the reading frame; this tends to produce a functional 
but truncated version of the dystrophin protein. BMD   
patients can usually walk and have a near normal life   
span and there is a 50% chance of them developing cardiac 
problems [5]. 
  DMD patients are normally diagnosed clinically between 
3 and 6 years of age, presenting with a delay in their motor 
development and weakness of the skeletal muscle. As the 
disease progresses the boys have problems walking; this is 
due to the wasting and atrophy of the muscles and as the 
muscles become wasted contractures form. The muscle 
weakness and the contractures together generally result in 
the boys becoming wheelchair bound around 10-12 years of 
age. Almost all skeletal muscles are affected in DMD with 
the muscle groups in the limbs preferentially affected, fol-
lowed by the trunk muscles, then the respiratory muscles. 
Patients used to die in their late teens or early twenties 
mainly from pulmonary problems. However, because of ad-
vances in respiratory care, such as nocturnal and continuous 
24-hour ventilator support, the life expectancy of DMD pa-
tients has increased to their late twenties to mid thirties and 
some patients may survive into their forties. In these older 
DMD patients, the major cause of death is now the result  
of the progression of the cardiac problems [4]. Therefore,   
the management of the cardiomyopathy is becoming a more 
important consideration in planning the care of older DMD 
patients. 
  Preclinical cardiac involvement has been reported in 25% 
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patients between the ages of 6-10 years and then declining in 
incidence with age [6]. Clinically apparent cardiomyopathy 
becomes evident after 10 years of age and increases in inci-
dence with age, being present in virtually all patients over 18 
years of age [7]. Often the clinical aspects of the cardiac de-
fects associated with DMD are masked by the muscle weak-
ness, which causes reduced physical activity in these boys. 
The progressive dilated cardiomyopathy (DCM) that devel-
ops in DMD boys is presumed to be a secondary conse-
quence of the fibrosis within the myocardium. In both skele-
tal and cardiac muscle, the function of dystrophin is to pro-
tect against contraction-induced damage. In skeletal muscle, 
there exists a resident stem cell population, the satellite cells, 
which can repair the damaged fibres even though the repair 
is still with dystrophin deficient cells. This means that the 
regenerative capacity of skeletal muscle is severely impaired 
leading to the eventual replacement of skeletal muscle with 
fatty and fibrotic material. However, there are no stem cells 
in the heart to regenerate the damaged cardiomyocytes so 
damaged cardiomyocytes will tend to die and be replaced by 
fibrotic tissue earlier than skeletal muscle. Therefore, the 
heart is potentially at greater risk than the skeletal muscle 
and the result of this cardiomyocyte damage and replacement 
with fibrotic material is that currently 10-50% of DMD   
patients die as a result of heart failure [8, 9]. 
DYSTROPHIN IN THE CARDIOMYOCYTE 
  Specifically, the absence of the dystrophin protein in the 
heart results in the development of a DCM [10]. As with 
skeletal muscle the loss of dystrophin and the disruption of 
the DGC (Fig. 1) results in the sarcolemma of the cardio-
myocyte becoming more fragile and susceptible to damage 
from muscle contractions, leading to small tears in the car-
diomyocyte membrane. Recent studies suggest that absence 
of dystrophin may disrupt the function of the sarcolemmal 
stretch-activated ion channels, which respond to mechanical 
stress [11]. It appears that the stretch-activated ion channels 
do not open appropriately in dystrophin deficient cardio-
myocytes when they are stretched during ventricular filling; 
this causes an increase in the influx of calcium into the car-
diomyocyte [12]. The tears in the cardiomyocyte cell mem-
brane allow the entry of extracellular calcium into the mus-
cle fibre raising the intracellular calcium levels (Fig. 2). The 
increase of the intracellular concentration of calcium in the 
cardiomyocyte leads to the activation of calcium-activated 
proteases such as calcium-induced calpains, a family of pro-
teases, which will degrade troponin I and thus compromise 
the contractions of the cardiomyocyte [13-15]. The activa-
tion of these calpains also mediate the destruction of the car-
diomyocyte plasma membrane proteins, which cause even 
 
Fig. (1). A schematic diagram of the position of dystrophin and its connection with the members of the dystrophin-glycoprotein complex 
(DGC). Dystrophin acts as a link between the basal lamina and the actin cytoskeleton helping to maintain the integrity of the sarcolemma. 
The loss of dystrophin compromises the DGC and leads to a more fragile sarcolemma. 
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more holes in the sarcolemma and allowing even more cal-
cium to enter the cardiomyocyte and further damage to the 
cardiomyocyte. Eventually this chronic calcium overload 
leads to the death of the cardiomyocyte (Fig. 2) [16]. The 
increased permeability of the sarcolemma and the degrada-
tion of muscle proteins also results in the release of intracel-
lular muscle proteins from the myofibre, such as creatine 
kinase (CK). Serum CK levels may reach 200-300 times 
above normal and consistently raised serum CK levels are 
used as a diagnostic and predictive marker for the extent of 
the muscle damage in DMD and BMD. This is because the 
serum CK values vary with the age and the degree of muscle 
damage and thus correlate with the clinical progression in 
both DMD and BMD [17]. 
  Cardiomyocytes possess several distinctive characteris-
tics, which contribute to the deterioration of the heart in 
DMD and BMD patients. It has already been mentioned that 
there are no stem cells to replace lost cardiomyocytes once 
they die but in addition there are other unique characteristics 
that contribute to the development of the DCM in DMD. 
Firstly, cardiac muscle will repeatedly contract around 
86,400 times per day whereas skeletal muscle will only con-
tract intermittently when needed to move a part of the body. 
These continual contractions result in constant fluxes in the 
intracellular calcium levels associated with each excitation-
contraction cycle, which undoubtedly accelerates the deterio-
ration process within the cardiomyocytes compared to skele-
tal myofibres. Secondly, the contraction of the cardiomyo-
cytes is based on a calcium-induced calcium release manner, 
which means that only a small amount of extracellular cal-
cium is needed to enter the cell to induce larger amounts of 
intracellular calcium to be released into the cytoplasm. When 
the sarcolemma of the cardiomyocyte becomes leaky be-
cause of the lack of dystrophin it means that more extracellu-
lar calcium is now able to leak into the cardiomyocyte. The 
L-type calcium channels can be activated unnecessarily, 
causing the release of intracellular calcium and actually initi-
 
Fig. (2). A flow diagram of the known pathways by which the loss of dystrophin or a severely truncated dystrophin leads to the development 
of cardiomyocyte death. 268    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Ameen and Robson 
ating contraction of the heart, leading to extra contractions of 
the DMD hearts [18]. These extra contractions caused by the 
leaky sarcolemma and higher intracellular calcium levels are 
manifest as arrhythmias, which also directly cause more 
damage to the cardiomyocytes as more tears will be gener-
ated in the membrane. Ultimately, the elevated intracellular 
calcium concentration activates the cascade of protein deg-
radation and cardiomyocyte death. There is therefore a vi-
cious cycle initiated by the loss of dystrophin plus the car-
diomyocyte is particularly susceptible to damage and there is 
no regenerative capacity in the heart to replace the lost car-
diomyocytes all of which leads to the development of the 
cardiomyopathy. 
CARDIOMYOCYTE FIBROSIS AND DILATION OF 
THE HEART 
  The cardiomyocyte death usually occurs in very discrete, 
localized small areas of the heart which have been referred to 
as ‘microinfarcts’ [19]. These microinfarcts can often be 
accompanied by chest pain in the patients and diagnosed by 
the release of cardiac troponin into the serum [19]. Within 
these focal necrotic areas, there is an inflammatory cascade, 
which is initiated by the death of the cardiomyocytes. 
Macrophages migrate into the heart to remove the damaged 
and dead cells (Fig. 3). Once the macrophages have removed 
the cardiomyocyte debris, fibroblasts then invade the dam-
aged area and form a fibrocollagenous scar tissue resulting in 
the deposition of fibrotic tissue in the walls of the heart, 
which replace the contractile cardiomyocytes. These fibrotic 
areas are very inflexible compared to the normal cardiac 
muscle that it replaces and thus there is a reduction in the 
efficiency of myocardial contraction. For reasons that are 
still unclear, the fibrosis begins in the left ventricular wall in 
DMD and in the right ventricular wall in BMD and there is 
sparing of the atria. In both DMD and BMD, the fibrosis of 
the heart starts on the outside of the ventricular wall, so start-
ing in the epicardium and progresses into the endocardium 
[20]. This pattern of fibrosis is unique to the dystrophi-
nopathies [7, 20]. As the fibrosis progressively spreads 
throughout most of the outer half of the ventricular wall it 
causes the ventricle to gradually stretch and enlarge, result-
ing in the ventricular wall becoming thinner, leading to a 
loss of contractility. The result of this thinning and enlarge-
ment of the ventricle is the formation of a DCM in DMD and 
BMD patients. The volume of the left ventricle will increase 
because of the enlargement of the chamber but there will be 
a decrease in systolic function, and there is often mitral valve 
regurgitation due to the valves no longer meeting because of 
the enlargement of the ventricle. The result of all these 
changes is that there is a decrease in the cardiac output and 
hemodynamic decompensation [21]. 
DCM PATHOLOGY SPECIFIC TO DMD AND BMD 
  In addition to the development of the DCM many DMD 
patients also develop arrhythmias, as a result of the increased 
intracellular calcium causing extra contractions, and these 
contribute significantly to the clinical progression. There can 
be sinus node dysfunction, atrioventricular node dysfunction, 
atrial fibrillation and ventricular tachycardia/fibrillation, 
which can develop at any time but which become more 
common with age and as the damage to the sarcolemma of 
the cardiomyocytes increases. Screening of all DMD boys is 
done by echocardiography and electrocardiogram (ECG) and 
it is recommended that they are screened at regular intervals 
after the age of 10 and these screens should ideally be per-
formed at least annually [6, 22].  
 
Fig. (3). A flow diagram of how the death of the cardiomyocytes 
caused by the lack of dystrophin then develops into the dilated car-
diomyopathy seen in DMD patients. 
  It has been reported that 90% of DMD patients have ab-
normal ECG readings. From the 12 lead ECG the irregular 
conduction patterns can be recognized which cause a promi-
nent Q wave in leads I, aVL, V5, and V6, or leads II, III, 
aVF, V5 and V6 [23]. Tall R waves in V1, and an R/S ratio 
of greater than 1 [24]. A shortened PR interval has also been 
reported in about 50% of patients and this is the most com-
mon ECG change in DMD patients [23]. Although there do 
appear to be differences between young and older individu-
als, with abnormal Q waves or Q/R ratios in younger indi-
viduals and a high-grade ventricular ectopy being more fre-
quent in older subjects [25]. Resting sinus tachycardia, a loss 
of the hearts circadian rhythm, and heart rate variability 
which is the result of increased sympathetic activity can be 
observed when Holter ECG monitoring is used in DMD pa-
tients [26]. It has also been reported that there is no differ-
ence in the ECG findings of DMD patients who have been 
diagnosed with DCM and those that are still in the subclini-
cal stage, indicating that the ECG changes begin before the 
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findings is therefore not very useful in diagnosing and moni-
toring the progression of the cardiomyopathy. 
  In DMD, the myocardial fibrosis and dilation tends to 
appear first in the left ventricular wall behind the posterior 
mitral valve leaflet. The fibrosis progresses inferiorly toward 
the apex of the heart and into the interventricular septum; 
eventually the entire left ventricle will be affected and the 
interventricular wall of the right ventricle [7, 27, 28]. In 
BMD patients, the pattern of the fibrosis progression is simi-
lar to that observed in DMD patients but the right ventricle is 
affected preferentially rather than the left [7]. Echocardio-
gram and magnetic resonance imaging (MRI) can visualize 
the posterior thinning of the epicardium, the areas of dyski-
nesis and akinesis, as well as giving a direct measurement of 
the systolic and diastolic dysfunction. The E point-to-septal 
separation (EPSS) is a measure of the minimal separation 
between the mitral valve anterior leaflet and the ventricular 
septum during early diastole [29]. An EPSS of greater than 
5–5.5 mm suggests that the left ventricle has become more 
spherical [29]. The sphericity index, calculated by dividing 
the length of the left ventricle by the width of the left ventri-
cle, is useful in evaluating the shape of the chamber of the 
left ventricular. A sphericity index of greater than 0.66 sug-
gests DCM [30]. Other signs of dilation include increased 
left ventricular diameter and volume, decreased shortening 
and ejection fractions, and development of mitral valve re-
gurgitation. 
DIAGNOSIS OF CARDIOMYOPATHY IN DMD   
PATIENTS 
  A diagnosis of cardiomyopathy in DMD patients is not 
easy because they tend to have a reduced exercise tolerance, 
which masks the cardiac problems. The fact that in DMD 
patients there is immobility, deformities, and pulmonary 
failure additionally obscure the clinical and radiographic 
signs and symptoms of heart failure. The standard diagnostic 
tool is echocardiography and annual echocardiograms after 
the age of 10 are recommended. However, echocardiogra-
phy, although readily available, gives only a crude indication 
of the heart problems and it is made more difficult in DMD 
patients by the development of scoliosis, which hampers the 
accurate measurements of the chambers of the heart. 
 Multigated cardiac radionuclide ventriculography 
(MUGA) is not affected by these problems and has been 
found to be sensitive in detecting subclinical cardiomyopa-
thy in DMD, BMD and female carriers [6, 31]. MUGA was 
able to detect a predominant systolic and minor diastolic left 
ventricular dysfunction even in the BMD patients and female 
carriers where there was no skeletal muscle involvement 
[31]. However, MUGA is associated with repeated radiation 
exposure, which becomes more relevant in DMD when an-
nual screening of cardiac function is recommended to moni-
tor the function of the heart and the progression of the car-
diomyopathy in DMD patients. Therefore, although MUGA 
has been shown to be as sensitive as echocardiography at 
detecting subclinical cardiomyopathy in DMD is has not 
been proven to be superior to echocardiography in assessing 
the systolic function. In addition MUGA is not available in 
all centers and it is expensive to perform. 
  Tissue Doppler can be used to identify myopathic 
changes that happen early in the development of the cardio-
myopathy and may also reflect the ongoing damage to the 
heart [27]. MRI has been suggested as another non-invasive 
method of monitoring the cardiac function in DMD patients. 
There is no ionizing radiation used in MRI and with the 
newer MRI machines high-resoultion images can be ob-
tained. The T2 relaxation time can be used to quantitate the 
tissue characteristics of the heart as it reflects the differences 
in water and fat content of the muscle [32]. However, MRI is 
expensive and not all centers have access to such a facility, 
but it is certainly more sensitive at detecting the cardiomy-
opathy when it is in the sub-clinical stage than many of the 
other methods available. 
  New diagnostic and prognostic biomarker tests using the 
natriuretic peptides, brain natriuretic peptide (BNP) and N-
terminal proBNP (NTproBNP), have proven to be useful 
diagnostic factors for patients with heart failure [22, 33-35]. 
In DMD, patients that were not on mechanical ventilation the 
plasma levels of BNP were associated with systolic dysfunc-
tion [36]. The combination of the plasma levels of natriuretic 
peptides linked to the echocardiogram have proven to be 
capable of evaluating the left ventricular function to a level 
that is comparable to the results obtained from MUGA [6, 
36]. A further advantage of using the levels of the natriuretic 
peptides in combination with echocardiograms is that it is 
less time consuming and does not cause distress to the pa-
tients [6]. However, whatever method is employed to test the 
heart the overriding principal is to decide what degree of 
weakening of the heart should initiate medical intervention. 
The traditional view is that treatment should start when there 
are overt signs of heart weakening and early intervention is 
inappropriate. This view is now being challenged as more 
data become available from animal model studies and human 
patients as to the pathophysiology of the DCM in DMD. 
PRESENT TREATMENT FOR DMD CARDIOMY-
OPATHY 
  The general therapy for DMD includes the use of gluco-
corticoids around the age of 5 or 6. The side effects of these 
drugs limit the effectiveness of long-term use but they have 
proven to slow the progression in the wasting of the skeletal 
muscle and can delay the use of a wheelchair by 1 to 2 years. 
There is now a movement to prolong the use of the steroids 
even after the boys become wheelchair bound as there is 
some evidence that it may help to maintain the cardiac and 
pulmonary function. In addition to the steroids, specific 
pharmacological treatment should be offered to all DMD and 
BMD patients with cardiac complications. At present treat-
ment using  adrenergic blockade and inhibition of ACEs 
have proven to be effective at remodeling the heart [37].  
  The progressive cardiac fibrosis that develops in DMD 
eventually leads to increased stress in the ventricular wall, 
and decreased cardiac output. The decrease in cardiac output 
leads to activation of the renin-angiotensin aldosterone sys-
tem (RAAS), which is vital in the regulation of sodium and 
water in the body. The first RAAS component activated is 
renin, an enzyme that cleaves angiotensinogen to form an-
giotensin I. Eventually, the ACE produced by endothelial 
cells in the lungs, transforms angiotensin I to angiotensin II. 
Angiotensin II stimulates the adrenal cortex to secrete aldos-
terone, promoting fluid and sodium retention. Both angio-
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sis and the deposition of connective tissue within the heart. 
Specifically, angiotensin II acts as a growth factor at sites of 
tissue repair and enhances the activity of transforming 
growth factor beta (TGF-1), which then stimulates the 
proliferation of the fibroblasts that cause the deposition of 
the fibrotic material in the walls of the heart [38-40]. 
Similarly, aldosterone is involved in the synthesis of fibrosis 
forming collagen [41]. These harmful consequences of 
RAAS hyperactivity secondary to decreased cardiac output 
further complicate the myocardial fibrosis resulting from 
dystrophin deficiency in DMD and BMD patients. 
Therefore, the use of ACE inhibitors, angiotensin receptor 
blockers (ARBs), and aldosterone antagonists in DMD and 
BMD patients with cardiomyopathy is recommended. 
  An uncontrolled retrospective study showed that echo-
cardiographic parameters, including left ventricular ejection 
fraction, fractional shortening, and sphericity index, in DMD 
and BMD patients improved 3 years after administration of 
either ACE inhibitors alone or the combination of both ACE-
inhibitors and -blockers [42]. Around the same time, a dou-
ble-blind multicenter study was conducted to evaluate the 
effect of preventive afterload reduction in muscular dystro-
phy patients. In this study, DMD patients between 9.5 and 13 
years old with normal ventricular function were randomly 
assigned to receive 3 years of placebo or perindopril, an 
ACE inhibitor. After this 3-year period, every participant 
received 2 years of perindopril. At the conclusion of the 
study, a lower left ventricular ejection fraction was found in 
those subjects who did not take perindopril for the first 3 
years [43]. The findings of this study not only suggested the 
beneficial effects of perindopril but also encouraged early 
pharmacological interventions to preserve cardiac function. 
A later study in 2006 tested another ACE inhibitor, enalapril, 
and monitored left ventricular systolic dysfunction in DMD 
patients with DCM, diagnosed based on left ventricular frac-
tional shortening. Normalization of fractional shortening 
occurred in 43% of the patients on enalapril [44]. This im-
provement was maintained for up to 4 years and again sug-
gests that earlier intervention may prevent the worsening of 
the subclinical cardiomyopathy in to full blown clinical 
DCM in a significant proportion of DMD patients. 
  New treatments based on the fundamental pathogenesis 
of DMD are now also being used clinically. As the entry of 
calcium into the cardiomyocyte is a major feature, leading to 
the fibrosis of the heart it has been proposed that the use of 
calcium channel blockers, such as diltiazem, flunarizine, and 
nifedipine would be beneficial for DMD [45-48]. However, 
no positive improvements have been reported and so the use 
of calcium blockers has not proven successful. 
  The use of low dose potassium sparing diuretics, such as 
spironolactone or eplerenone has been shown to be able to 
slow or prevent the development of the fibrosis [49, 50]. The 
downside of potentially combining spironolactone and ACE-
inhibitors is that it can result in the building up potassium in 
the blood and therefore requires careful monitoring by fre-
quent blood tests. The use of anti-oxidants has also been 
proposed as useful for both the heart and skeletal muscle 
pathology in DMD, and as a rule, these have no serious in-
teractions with the other drugs and can be relatively easily 
introduced into the treatment regime of the DMD boys. 
However, the downside is that it increases the number of 
medications that the boys have to take every day. 
  A major problem in understanding the results of the 
clinical trials so far tested for treatment of the cardiomyopa-
thy in DMD patients is the still relatively small number of 
patients that are available to enter trials, and we just do not 
have the numbers of suitable patients to try all the suggested 
treatments. In such cases, the testing of potential new treat-
ments in the available animal models of the disease becomes 
essential. The animal models also allow the pathophysiology 
of the cardiomyopathy to be investigated further. There are a 
number of animal models, which are genetic equivalents to 
the human DMD. 
AVAILABLE ANIMAL MODELS OF DMD: ADVAN-
TAGES AND DISADVANTAGES 
Cardiomyopathy in the Mdx Mouse 
  The mdx mouse despite being a genetic homolog to 
DMD has not been fully validated as a model for dystrophin 
deficient cardiomyopathy. The relatively mild phenotype and 
near normal life span of the mdx mouse has prompted the 
generation of double mutants such as the mdx/utrophin and 
the mdx/MyoD mice, both of which have a far more severe 
skeletal and cardiac muscle phenotype to model the devel-
opment of cardiomyopathy. Both of these double knockouts 
(DKO) have been proposed as a more accurate model system 
for the study of the cardiomyopathy that develops in DMD 
and for the testing of new therapeutic options. However, the 
mdx mouse does develop cardiomyopathy and can be a suit-
able model for the human DMD cardiomyopathy although it 
develops the cardiomyopathy very late in its life [51]. 
  The mdx mouse like the DMD patient has a complete 
loss of dystrophin from the cardiomyocytes. By 10 months 
of age the mdx mouse does display signs of a DCM with 
hypertrophied hearts, which have poor contraction and beat 
at a slower rate than normal [51]. The contraction speed and 
the force are significantly altered in the atria even in young 
mice and this is found before there is any obvious necrosis 
and resulting fibrosis of the walls of the ventricles of the 
heart. The fact that there are these early changes, before any 
major fibrosis, suggests that the impaired function is not a 
consequence of the fibrosis or cardiomyocyte death but is 
related to the membrane ion channels that regulate calcium 
entry into the cardiomyocyte. In the mdx mouse, although 
the left ventricular systolic function is initially normal in 2-
month-old mice, by 1 year old a DCM starts to develop and 
this is accompanied by interstitial fibrosis [51]. The ECGs of 
conscious mdx mice younger than 10-12 weeks old are more 
or less normal but around 10-12 weeks they begin to show 
similar abnormalities to those observed in DMD patients 
[52]. Other studies have shown that even at 8 weeks the mdx 
heart is more susceptible to damage when subjected to me-
chanical stress [53]. These studies highlight a major consid-
eration when using the mdx mouse for studying the disease 
processes of DMD - under normal housing conditions the 
heart and the skeletal muscles of the mdx mouse are not 
stressed, and there is therefore only minimal damage caused 
to the heart and skeletal muscles, so the mdx mouse displays 
a milder phenotype. The reduced stress placed on the heart 
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opathy around 10-12 months of age compared to the rela-
tively earlier development in DMD boys. However, if the 
heart and the muscles are stressed by making the mdx mouse 
exercise or by ex vivo manipulations of the heart then the 
mechanisms for damage are present and the heart and mus-
cles behave more like those of the human DMD patients. 
  The difference in the speed and pathological location of 
the cardiomyopathy that develops under normal and exercise 
regimes is highlighted by two studies. The first is by Quinlan 
et al. which reported that the fibrosis they observed in the 
hearts of aged mdx mice was patchy and occurred equally in 
both the left and right ventricles [51], whereas in DMD the 
fibrosis is predominately in the left ventricle. In contrast, the 
study by Nakamura et al. reported fibrotic changes in the left 
ventricle, and this is more comparable to that reported in 
DMD patients [54]. When the study designs of these two 
studies are analyzed it can be seen that Nakamura et al. used 
regular treadmill exercises for their mdx mice, which greatly 
increased the amount of left ventricular pathology seen, 
compared to the study by Quinlan et al. where the mice were 
not subjected to any exercise regimes. 
  In conclusion, the mdx mouse shares many but not all the 
feature of the DCM seen in DMD patients. The differences 
seen in the mdx mouse may be a question of scale and the 
size of the hearts between humans and mice and the exercise 
regimes used for the mdx mouse. Taking these factors into 
consideration the mdx mouse can provide useful information 
on the pathophysiology of the cardiomyopathy in DMD and 
with careful study design can be used to test new therapeutic 
targets for DMD cardiomyopathy. 
  As mentioned earlier both the milder BMD and DMD 
female carriers have also been reported to develop cardio-
myopathy and to have impaired heart function. The het-
erozygote female mdx mice on the classic C57Bl/10 back-
ground do not develop a cardiomyopathy; even though dys-
trophin is expressed in only half of the cardiomyocytes, this 
mosaic expression of dystrophin is enough to prevent stress-
induced heart damage [55]. Even by 21 months of age the 
hearts of the female mdx carrier mice do not display any 
cardiac phenotype and all physiological parameters were 
within the normal range whereas the hearts in the homozy-
gote mdx by this time are displaying significant cardiomy-
opathic changes [56, 57]. It was also noted that utrophin was 
upregulated in the hearts of the female mdx carrier mice and 
this may compensate for the reduced dystrophin in the car-
diomyocytes [58]. This study also suggests that an almost 
complete prevention of the DMD cardiomyopathy may only 
require a 30-50% mosaic dystrophin expression; this is   
encouraging as 100% re-expression of dystrophin is not   
feasible by any gene and or cell based therapy at the moment. 
MDX/UTROPHIN DOUBLE DEFICIENT MICE AND 
CARDIOMYOPATHY  
  Utrophin is a related protein to dystrophin and is devel-
opmentally expressed with the same distribution as dystro-
phin. It is downregulated as dystrophin begins to be ex-
pressed and begins to replace it. In the adult, utrophin is only 
found at the neuromuscular junction where it helps to stabi-
lize the junctional membrane. The loss of utrophin has no 
effect on the phenotype of mice in isolation, as dystrophin is 
the major structural protein of the muscle fibres. Utrophin is 
upregulated in the mdx mouse and its expression is located 
around the sarcolemma suggesting that it may partially com-
pensate for the loss of dystrophin and perhaps to some extent 
explains the milder phenotype of the mdx mouse. The DKO 
mice that have no dystrophin or utrophin have a much more 
severe phenotype than the mdx mouse. They show all the 
clinical symptoms of DMD and the mice normally die by 20 
weeks of age [59, 60]. Although the DKO mice do not die 
from heart failure it has been shown that there is inflamma-
tion and cardiomyocyte degeneration and fibrosis in the 
hearts of the double mdx/utrophin knockout mice. The sever-
ity of the heart problems is of a similar level as that seen in 
the aged mdx mouse; the advantage is that in these DKO 
hearts the cardiomyopathy develops much earlier [61]. By 2 
months of age the DKO mice have abnormal ECG patterns 
with a drastically decreased S-R wave ratio and faster heart 
rates whereas the same changes are not noted until 6 months 
of age in the mdx mouse. These ECG abnormalities along 
with the polyphasic R wave have been reported in 70-80% of 
DMD patients. There is also a significant impairment of the 
contractile function in the DKO compared to the mdx mouse 
accompanied by impaired relaxation and a depressed -
adrenergic response [62]. Whereas it appears that dystrophin 
is able to fully compensate for the loss of utrophin in the 
single utrophin knockout mouse, the opposite is not true as 
there is significant dysfunction in the mdx even if it takes 
longer to become manifest, so utrophin is not able to fully 
compensate for the loss of dystrophin. 
  In the mdx/utrophin DKO an increased expression of the 
71 integrin is able to ameliorate the development of the 
muscular dystrophy [63]. In both the mdx mouse and DMD 
patients there are increased levels of 71 and this leads to 
the question of whether increasing the levels of 71 might 
improve the muscle pathology by helping to stabilize the 
muscle membrane. Increasing the 71 level in the 
mdx/utrophin DKO does help to maintain the structural in-
tegrity of the myotendinous and neuromuscular junctions. In 
addition, the regenerative capacity of skeletal muscle was 
also increased. The upregulation of 71 also reduced the 
development of the cardiomyopathy associated with this 
DKO. However, the transgenic 7 transcripts were not seen 
in the heart and thus the cardiomyopathy is a secondary 
manifestation of the skeletal muscle pathology [64]. 
  While this last study suggests that at least a part of the 
pathophysiology of the cardiomyopathy is not directly re-
lated to the lack of dystrophin in the cardiomyocytes but is a 
secondary consequence of the skeletal muscle pathology, 
there is still considerable evidence that the lack of dystrophin 
has severe consequences on the function of the cardiomyo-
cytes. Therefore, restoring the vital link between the cy-
toskeleton and the DGC in only 20-30% of the cardiomyo-
cytes and skeletal muscle may be enough to prevent the de-
velopment of the cardiomyopathy and muscle damage. Cer-
tainly if dystrophin is restored in around 50% of the mdx 
cardiomyocytes this is able to completely prevent the stress-
induced cardiomyopathy and cause the return to a normal 
left ventricular function [55]. Therefore, there is hope that if 
the various gene therapy strategies that are in clinical trials at 
the moment can re-establish an exon skipping, truncated 
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as the skeletal muscle then there is a possibility of improving 
the cardiac function in DMD. 
MDX/MYOD DOUBLE KNOCKOUTS AND CAR-
DIOMYOPATHY 
  MyoD is basic-helix-loop-helix myogenic determination 
transcription factor that is not expressed in the heart but is 
expressed in all skeletal muscle committed cells. In the 
MyoD knockout skeletal muscle forms normally, this is be-
cause there is compensation from the other members of the 
MyoD family of transcription factors that are able to substi-
tute for the loss of MyoD. The double mdx/MyoD knockout 
mice show pronounced myopathic changes caused by the 
reduction in the skeletal muscles ability to regenerate as the 
satellite cells that are the resident stem cell population re-
quire MyoD for their proper differentiation [65]. As MyoD is 
not expressed in the heart, any myocardial changes that are 
seen are the result of increased muscle damage and worse 
muscle regeneration. These DKOs do develop a severe car-
diac myopathy. When the hearts are analyzed, there are areas 
of fibrosis made up of necrotic myocytes and these areas are 
associated with hypertrophied myocytes. The areas of fibro-
sis were confined to the epicardial region of the left ventricle 
mainly, which is similar to the fibrosis seen in DMD [66]. It 
has also been reported that the cardiomyocyte hypertrophy 
seems to precede the necrosis, suggesting that the hypertro-
phied cardiomyocytes are more susceptible to damage. 
  It has been suggested that this animal model is the best 
and most accurate murine model for DMD that is currently 
available and as such, some work has started on using this 
model to understand the pathophysiology of the cardiomy-
opathy that develops in DMD. The role of p38 and JNK-1 
kinases in the development of the dystrophin-associated car-
diomyopathy has been suggested as an early stage change 
that may lead to the later cardiomyopathy [67]. Phosphory-
lated p38 was dramatically reduced in the hearts from 10-
month-old mice where there are significant cardiomyopathic 
changes in the mdx/MyoD DKOs compared to the levels 
observed at 7 months where the hearts are still relatively 
undamaged. In contrast, tyrosine phosphorylation of JNK-1 
was elevated in the damaged hearts of the mdx/MyoD 
DKOs. 
FELINE MODELS OF DMD 
  A colony of cats that are deficient in dystrophin have 
been identified [68, 69]. These cats develop a hypertrophic 
feline muscular dystrophy (HFMD), the muscles in these 
cats show multifocal areas of degeneration and regeneration 
and there is a wide variation in the muscle fibre diameters 
[69, 70]. However, muscle fibrosis has not been observed in 
the HFMD model, whereas in DMD there is skeletal muscle 
atrophy and the replacement of muscle with fibrotic tissue. 
In addition in the HFMD cat there is severe progressive 
muscle fibre hypertrophy especially of the diaphragm, the 
reverse of what is seen in DMD patients were the diaphragm 
is one of the muscles that undergoes severe muscle fibre at-
rophy and fibrosis which leads to the development of the 
respiratory problems seen in DMD patients [68, 69, 71]. The 
HFMD cats do though develop cardiomyopathy [70]. The 
changes in the hearts in the HFMD cats have been reported 
in affected males and females and the obligate female carri-
ers [70]. There is early onset of concentric myocardial hyper-
trophy which is seen in all adult cats, these lesions were pre-
dominantly in the left ventricle, interventricular septum and 
the papillary muscles, they are also mainly seen in the endo-
cardium [70]. However, because there is myocardial hyper-
trophy clinical signs of heart failure are very rare in the 
HFMD model. The HFMD model is therefore not a good 
model system for the study of the DMD cardiomyopathy, as 
it does not mirror the human condition. 
CANINE MODELS OF DMD AND CARDIOMYO- 
PATHY 
  There are several different canine models of DMD, in-
cluding the two most studied canine models: the golden re-
triever muscular dystrophy (GRMD) and the beagle model of 
canine based x-linked muscular dystrophy (CXMD). The 
advantage of these canine models of DMD is that they tend 
to display a far more severe phenotype that mirrors the hu-
man progression far better than the mdx mouse. In both the 
GRMD and the CXMD there is severe muscle atrophy in the 
limbs that lead to joint contractures and dysphagia. The 
GRMD shows similar ECG findings as those reported in the 
human DMD patients and there is a progressive cardiomy-
opathy that is comparable to the cardiomyopathy in DMD 
[28, 72-74]. This makes the GRMD a very useful model to 
explore the pathophysiology and testing of potential new 
treatment options. However, the size of the GRMD makes it 
difficult and expensive to maintain any colony and this re-
stricts its use. 
  The beagle is a medium sized dog making the mainte-
nance of the CXMD colony more manageable. They also 
manifest abnormalities on echocardiograms and the cardiac 
pathology can be seen by 12 months of age. The abnormal 
and distinct deep Q-waves in leads II, III and aVF are seen 
around one year of age. The deep Q-wave has been thought 
to be due to the myocardial fibrosis in the posterobasal re-
gion of the left ventricle, but these changes are often seen 
before any changes on the echocardiograms. At 6-7 months 
of age there are no changes seen on the echocardiograms and 
no alterations in the function of the left ventricle. Therefore, 
the cardiac phenotype of the CXMD is milder than the 
GRMD but it is identical [75]. 
  The female carriers in the canine models have also been 
proven to mirror the human female carriers more accurately 
than those of the mdx mouse. Female carrier dogs have a 
significantly increased Q/R ration in leads V2 and V4 [72]. 
There were also changes in female carrier dogs noted on the 
echocardiograms that represent a calcified myocardium due 
to fibrosis of the myocardium and replacement of the car-
diomyocytes with dense connective tissue [72]. Therefore, 
both the canine models and their female carriers are a more 
accurate model for the cardiomyopathy that develops in the 
human DMD patients and the human female carriers. 
NEW TREATMENT OPTIONS FOR MUSCULAR 
DYSTROPHIES AND THE HEART 
  Despite the tremendous progress that has been made in 
the past several years in developing gene therapy that targets 
the skeletal muscle for treating DMD, few attempts have 
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study explored the potential of engraftment of fetal cardio-
myocytes in the mdx and a canine model of DMD [76]. 
However, the results were not encouraging as the dystrophin 
expression was limited to the transplanted cells. An addi-
tional problem has emerged from the targeted repair of the 
dystrophic skeletal muscle, as once the skeletal muscle is 
repaired it has a tendency to make the cardiomyopathy be-
come more apparent and severe than in the untreated mdx 
mice. Once again, this highlights the secondary damage on 
the heart from increasing the activity and mobility of the 
animal, which increases the stresses on the heart, composed 
of cardiomyocytes that are more fragile. These studies have 
emphasized the need to target both the skeletal and cardiac 
muscles to have an acceptable clinical outcome. 
  The present cell based therapies are based around the use 
of mesangioblasts rather than the satellite cells of the skeletal 
muscle. Mesangioblasts have several advantages over the use 
of satellite cells especially for the restoration of dystrophin 
to the heart as well as the skeletal muscle. They are multipo-
tent progenitor cells and can thus potentially make any 
mesodermal tissue including skeletal and cardiac muscle. 
They can also be delivered via the arterial system and so can 
target all the skeletal muscles around the body as well as the 
heart [77]. These mesangioblasts have proven in the GRMD 
model that they are able to restore dystrophin to the skeletal 
muscle [78]. In a recent study a cardiac mesangioblast popu-
lation has also been identified and isolated and has been 
shown to differentiate into cardiomyocytes when cultured in 
vitro and then injected into the infarcted myocardium [79]. 
Therefore, the principal that these mesangioblast may help to 
repair the cardiomyopathy in DMD has been proven. How-
ever, it has still to be shown conclusively that these cells can 
deliver sufficient improvement to both the skeletal and car-
diac muscle functions. 
  The reduced number of gene therapy attempts to repair 
the cardiac muscle rather than the limb muscle is the result 
of two problems. Firstly, cardiac muscle is harder to target 
than the muscles of the limbs because of its anatomical loca-
tion deeper in the body and because of its normal vital 
physiological function, as you do not want to disrupt the 
function of the heart during the procedure. Secondly, the size 
of the dystrophin cDNA exceeds the packaging capacity of 
the viral vectors that are currently available. This second 
problem has been an issue for all gene therapy treatments for 
DMD and has been addressed by using mini or micro-
dystrophin constructs. These mini-dystrophin constructs are 
on average around 30% of the size of the full length dystro-
phin cDNA reviewed by [80]. This will produce a BMD type 
phenotype that is capable of providing a functional im-
provement in the skeletal muscles of the mdx mouse [81]. 
Yue et al. showed that direct cardiac injection of an adeno-
associated virus (AAV) that delivered a micro-dystrophin 
gene to 12 hour old neonatal mdx mice was able to cause 
extensive expression of the micro-dystrophin in both the 
inner and outer layers of the myocardium even 10 months 
later [82]. This truncated mini-dystrophin formed a func-
tional connection with the DGC and improved the   
sarcolemma integrity of the cardiomyocytes. However, the 
direct injection of AAV vectors carrying a mini-dystrophin  
is unlikely to take off and a systemic treatment option that 
targets the skeletal muscle and the cardiac muscle at the 
same time is the ideal situation. 
  The restoration of the open reading frame in the mutated 
dystrophin gene using antisense oligonucleotides, which 
allow exon skipping over the mutated exons and create 
shortened transcripts that are able to generate a truncated but 
functional dystrophin have shown in small scale trials to be 
effective for improving the dystrophin expression in skeletal 
muscle [83]. Systemically delivered phosphorodiamidate 
morpholino oligomers (PMOs) have proven to be particu-
larly effective for skipping the mutated exon in the mdx 
mouse, exon 23, and producing dystrophin expression at 
therapeutic levels throughout the body in the skeletal mus-
cles of the mdx  mice. Unfortunately, although dystrophin 
could be restored in the skeletal muscles it was not detect-
able in the heart [84]. In a recent study the use of an argin-
ine-rich cell-penetrating peptide, conjugated PMO has been 
shown to successfully restore the dystrophin expression in 
the heart and to significantly improve the sarcolemma integ-
rity and prevent the development of the cardiomyopathy 
[85]. The treatment consisted of 2 cycles of 4 injections in 
each cycle (1 injection per day for 4 days) separated by a 2 
week period between week 8 to 16 weeks of age in the mdx 
mouse. This treatment was able to prevent the development 
of the cardiac hypertrophy and diastolic dysfunction by 5-6 
weeks after the treatment. Even with this short term treat-
ment regime and the resultant decline in the expression of 
the dystrophin gene by 12 weeks after treatment had fin-
ished, to less than 1% of the original expression level, the 
cardiac improvement continued for up to 7 months [85, 86]. 
These exon-skipping trials may provide a therapeutic ap-
proach that may not only prevent but also slow down the 
development of the cardiomyopathy in DMD patients. 
  The other major treatment option is to employ molecules 
that allow read-through of the stop codon in the dystrophin 
gene that causes the loss of the dystrophin protein in DMD. 
Antibiotics like gentamycin have the ability to suppress stop 
codons and the efficiency of the read-through varies in-
versely to the efficiency of a stop codon. Gentamycin treat-
ment of mdx mice was able to re-establish around 20% of 
the normal expression of dystrophin but this was highly vari-
able from animal to animal and human trials using gentamy-
cin have not proven effective. The strategy though is sound 
and the new drug PTC124 (Ataluren) when administered to 
the mdx mouse has resulted in the production of full-length 
functional dystrophin. It is also able to restore the dystrophin 
expression in the hearts of mdx mice after 4 weeks of treat-
ment [87]. Clinical trials of PTC124 have been extended 
because of the positive results that have emerged so far. 
  New pharmaceutical treatments have also been suggested 
for DMD cardiomyopathy from the results obtained in the 
mdx mouse. One such drug that has shown beneficial effects 
in the mdx mouse is sildenafil. Sildenafil is a phosphodi-
esterase 5 (PDE5) inhibitor and prevents the breakdown of 
cyclic guanosine monophosphate (cGMP), sildenafil has 
already been shown to prevent cardiac hypertrophy and im-
prove myocardial function in genetically normal mice that 
have been subjected to pressure overload [88, 89]. It has pre-
viously been shown that prior to the development of overt 
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functional abnormalities, specifically there is defective nitric 
oxide (NO) and this has knock on consequences for its cellu-
lar effector cGMP signaling [90]. Neuronal NO synthase 
(nNOS) is significantly downregulated in dystrophic hearts 
and its normal subsarcolemma distribution is disrupted so 
that it is found now in the cytoplasm of the cardiomyocyte. 
When the expression of nNOS is restored then it has been 
reported that the inflammation, fibrosis and ECG abnormali-
ties are prevented in the mdx mouse [52]. Sildenafil is able 
to enhance cGMP-signaling independent of NO formation; 
this has been reported to improve the contractile perform-
ance, metabolic status of the cardiomyocytes, and improves 
the sarcolemma integrity in mdx mice hearts [91, 92]. Thus, 
sildenafil constitutes a potential clinical pharmaceutical 
treatment for dystrophin related cardiomyopathies. 
  Another potential pharmaceutical treatment for DMD 
cardiomyopathy is the use of inhibitors of TGF-. This cyto-
kine is a likely mediator of the fibrosis that is seen in the 
cardiomyopathy. It is expressed at high levels in the skeletal 
muscles of DMD patients and its level has been shown to be 
related to the amount of fibrosis that develops in the skeletal 
muscle [93]. Pirfenidone is an orally active inhibitor of TGF-
 fibroblast induced growth and collagen synthesis in a 
number of different tissues. It has proven useful for a num-
ber of conditions that cause fibrosis of various organs such 
as pulmonary fibrosis, and glomerulosclerosis in a model of 
renal fibrosis [94-97]. Eight-month-old mdx mice treated 
with pirfenidone for 7 months had lower TGF- mRNA and 
displayed improved cardiac contractility that were equivalent 
to their wildtype littermates of the same age [98]. However, 
there was no change in the cardiac stiffness or the amount of 
fibrosis that developed in the pirfenidone treated mdx hearts 
[98]. The earlier administration of pirfenidone during the 
acute inflammatory stage might be effective at preventing 
the start of the fibrosis and help to maintain the function of 
the heart. 
  The loss of dystrophin from the DGC makes the cardio-
myocytes more susceptible to damage and causes tears in the 
membrane that then allow calcium to enter the cell. The ap-
plication of a membrane sealant poloxamer 188 in vitro has 
been shown to correct these defects [99]. In vivo administra-
tion of poloxamer 188 to mdx mice instantly improved the 
ventricular geometry and was able to block the development 
of acute cardiac failure after dobutamine mediated stress. 
There are still several hurdles to resolve over the optimal 
dosing and long-term effects of such chemical based mem-
brane sealants in humans. However, these do represent a new 
and novel therapeutic approach for preventing or reversing 
the progression of the skeletal and cardiac muscle pathology 
in DMD [99-101]. 
CONCLUSION 
  The present treatment options and frequent monitoring 
have led to a major improvement in the quality of life of 
DMD patients. However, the longer life span of DMD pa-
tients has revealed that the cardiomyopathy that develops is a 
major health issue that needs to be addressed. The traditional 
view that medications for the heart should only be started 
when overt symptoms become evident is now being chal-
lenged, as it may already be too late to significantly improve 
the function of the heart by this stage. Instead, treatments are 
now being initiated before overt symptoms are seen to help 
protect the heart from damage. Because of the increasing 
numbers of DMD boys who are now surviving longer and 
developing cardiomyopathy new treatment regimes are been 
examined using the numerous animal models available. The 
best animal model to study the cardiomyopathy in DMD is 
still debatable; the mdx is a milder phenotype, the DKO 
mouse models are DKOs and may have additional deficits, 
and the feline model is not a good model for DMD while the 
canine models are not readily available and are expensive. 
What may help, and has helped the skeletal muscle studies, 
is to have a set of agreed study protocols designed to achieve 
the best and most reliable results in the mdx mouse and use 
the other models as an additional source of information. 
Having a set of defined study protocols means that the re-
sults from various studies can be directly compared with 
each other and more importantly any results can be more 
easily translated into modifications in the treatment regimes 
for the human DMD patients. 
ABBREVIATIONS 
ACE-inhibitors =  Angiotensin  converting  enzyme-
inhibitors  
ARBs  =  Angiotensin receptor blockers  
BMD =  Becker  muscular  dystrophy 
CXMD  =  Canine based x-linked muscular 
dystrophy  
CK  =  Creatine kinase  
cGMP =  Cyclic  guanosine  monophosphate 
DCM =  Dilated  cardiomyopathy   
DKO =  Double  knockouts 
DMD =  Duchenne  Muscular  Dystrophy   
DGC =  dystrophin-glycoprotein  complex 
ECG =  Electrocardiogram 
EPSS  =  E point-to-septal separation 
GRMD  =  Golden retriever muscular dystrophy 
HFMD  =  Hypertrophic feline muscular dystro-
phy 
MRI  =  Magnetic resonance imaging 
MUGA  =  Multigated cardiac radionuclide ven-
triculography 
BNP  =  Brain natriuretic peptide 
nNOS =  Neuronal  NO  synthase 
NO =  Nitric  oxide 
NTproBNP =  N-terminal  proBNP 
PMOs  =  Phosphorodiamidate morpholino oli-
gomers 
PDE5 =  Phosphodiesterase  5 
RAAS =  Renin-angiotensin  aldosterone  system 
TGF-1  =  Transforming growth factor-beta Experimental Models of Duchenne Muscular Dystrophy  The Open Cardiovascular Medicine Journal, 2010, Volume 4    275 
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